<DOC>
	<DOCNO>NCT00103558</DOCNO>
	<brief_summary>This open label , Phase I/II , dose escalation research study investigational product call lumiliximab , give FDA ( Food Drug Administration ) approve product fludarabine , cyclophosphamide , rituximab ( FCR ) . The study duration 17 visit 42 month disease progress require additional CLL therapy . The total duration participation study approximately 4 year , however disease status follow indefinitely ( forever ) .</brief_summary>
	<brief_title>Lumiliximab Combination With FCR Subjects With Relapsed Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age : 18 year old Diagnosis Bcell CLL International Workshop CLL ( IWCLL ) response criterion Relapsed CD23+ Bcell CLL Rai Stage III IV , Rai Stage I II determine disease progression evidence rapid double peripheral lymphocyte count , progressive lymphadenopathy , progressive splenomegaly , B symptom Prestudy WHO Performance Status less equal 2 Signed , write Institutional Review Board ( IRB ) approve informed consent Men &amp; woman reproductive potential must agree follow accepted birth control method treatment 3 month completion treatment Acceptable liver function : Bilirubin le equal 2.0 mg/dL ( 26 Âµmol/L ) , AST ( SGOT ) &amp; /or ALT ( SGPT ) less equal 2 time upper limit normal Acceptable hematologic status : Platelet count less equal 50 x 10^9/L , ANC le equal 1 x 109/L Acceptable renal function : Serum creatinine less equal 1.5 time upper limit normal Subjects respond prior FCR therapy ( relapse within 6 month last dose ) . Cancer radiotherapy , radioimmunotherapy , biological therapy , chemotherapy , investigational therapy within 4 week prior Study Day 1 Previous exposure lumiliximab antiCD23 antibody Subjects prior allogenic bone marrow transplant ( BMT ) autologous BMT peripheral stemcell transplant ( PBSCT ) Known infection HIV , hepatitis B , hepatitis C Uncontrolled diabetes mellitus Uncontrolled hypertension Transformation aggressive Bcell malignancy ( e.g. , large Bcell lymphoma , Richter 's Syndrome , prolymphocyte leukemia ( PLL ) Subjects secondary malignancy require active treatment ( except hormonal therapy ) Subjects medical condition currently require longterm use ( less 1 month ) systemic corticosteroid Serious nonmalignant disease laboratory abnormality , , opinion investigator &amp; /or sponsor , would compromise protocol objective Active uncontrolled bacteria , viral , fungal infection New York Heart Association Class III IV cardiac disease , myocardial infarction within past 6 month prior Study Day 1 , unstable arrhythmia , evidence ischemia ECG within 14 day prior Study Day 1 Seizure disorder require anticonvulsant therapy Severe chronic obstructive pulmonary disease hypoxemia Major surgery , diagnostic surgery , within 4 week prior Study Day 1 Clinically active autoimmune disease Subjects history fludarabineinduced autoimmune cytopenia Pregnant currently breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>